BioCorRx Inc. (BICX)

OTCMKTS: BICX · Delayed Price · USD
2.05
+0.16 (8.47%)
Sep 30, 2022 4:00 PM EDT - Market closed
8.47%
Market Cap 14.53M
Revenue (ttm) 58,950
Net Income (ttm) -4.89M
Shares Out 7.09M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,672
Open 2.09
Previous Close 1.89
Day's Range 2.05 - 2.09
52-Week Range 1.00 - 7.50
Beta 0.88
Analysts n/a
Price Target 5.20 (+153.7%)
Earnings Date Nov 14, 2022

About BICX

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The... [Read more...]

Industry Medical Care Facilities
CEO Brady Granier
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol BICX
Full Company Profile

News

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...

3 weeks ago - GlobeNewsWire

BioCorRx Provides Business Update for the Second Quarter of 2022

ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related d...

1 month ago - GlobeNewsWire

BioCorRx to Participate in the Benzinga All Access Event on July 15th

ANAHEIM, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related d...

2 months ago - GlobeNewsWire

BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - July 6, 2022) - The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the...

2 months ago - Newsfile Corp

BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the...

ANAHEIM, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

3 months ago - GlobeNewsWire

BioCorRx Featured on LiveNOW from FOX

ANAHEIM, CA, June 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related d...

3 months ago - GlobeNewsWire

BioCorRx to Present at the LD Micro Invitational XII on June 7th

ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

4 months ago - GlobeNewsWire

BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting

Collaboration to create a synergistic treatment offering, combining BioCorRx's MAT treatment program and 2B3D virtual reality technology

4 months ago - GlobeNewsWire

BioCorRx Business Update for the First Quarter of 2022

ANAHEIM, CA, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire  – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related d...

4 months ago - GlobeNewsWire

BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opio...

ANAHEIM, CA, April 27, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relat...

5 months ago - GlobeNewsWire

BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th

ANAHEIM, CA / ACCESSWIRE / April 26, 2022 / BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs fr substance abuse and related disorders, today announce...

5 months ago - Accesswire

BioCorRX Inc. Discusses FDA Approval Process for Implantable Naltrexone Pellet, BICX104, with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - April 19, 2022) - The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to t...

5 months ago - Newsfile Corp

BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for t...

ANAHEIM, CA, April 11, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relat...

5 months ago - GlobeNewsWire

BioCorRx Provides 2021 Year-End Business Update

ANAHEIM, CA, April 01, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relat...

6 months ago - GlobeNewsWire

BioCorRx to Participate in Two Upcoming Conferences

ANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relat...

6 months ago - GlobeNewsWire

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone P...

ANAHEIM, CA, March 16, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relat...

6 months ago - GlobeNewsWire

BioCorRx to Present at the Q1 Investor Summit Conference on March 9th

Anaheim, California--(Newsfile Corp. - March 2, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, ...

7 months ago - Newsfile Corp

BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104

ANAHEIM, CA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related d...

7 months ago - GlobeNewsWire

BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference

ANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

8 months ago - GlobeNewsWire

BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board

ANAHEIM, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...

9 months ago - GlobeNewsWire

BioCorRx to Participate in the Benzinga All Access Event on December 2nd

ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...

10 months ago - GlobeNewsWire

BioCorRx Acquires Intellectual Property for Drug Delivery

Patent Application Covers Solid Implant Formulation for Drug Delivery

10 months ago - GlobeNewsWire

BioCorRx Provides Business Update for the Third Quarter of 2021

ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

10 months ago - GlobeNewsWire

BioCorRx to Present at the Q4 Investor Summit Conference on November 16th

Anaheim, California--(Newsfile Corp. - November 10, 2021) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorde...

10 months ago - Newsfile Corp

BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant

ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorde...

11 months ago - GlobeNewsWire